TG Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TGTX and other ETFs, options, and stocks.

About TGTX

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. 

CEO
Michael Sean Weiss
CEOMichael Sean Weiss
Employees
399
Employees399
Headquarters
Morrisville, North Carolina
HeadquartersMorrisville, North Carolina
Founded
1993
Founded1993
Employees
399
Employees399

TGTX Key Statistics

Market cap
8.25B
Market cap8.25B
Price-Earnings ratio
16.81
Price-Earnings ratio16.81
Dividend yield
Dividend yield
Average volume
2.72M
Average volume2.72M
High today
$50.19
High today$50.19
Low today
$49.11
Low today$49.11
Open price
$49.96
Open price$49.96
Volume
709.76K
Volume709.76K
52 Week high
$59.30
52 Week high$59.30
52 Week low
$25.28
52 Week low$25.28

Stock Snapshot

TG Therapeutics(TGTX) stock is priced at $49.87, giving the company a market capitalization of 8.25B. It carries a P/E multiple of 16.81.

As of 2026-08-07, TG Therapeutics(TGTX) stock has fluctuated between $49.11 and $50.19. The current price stands at $49.87, placing the stock +1.5% above today's low and -0.6% off the high.

TG Therapeutics(TGTX) shares are trading with a volume of 709.76K, against a daily average of 2.72M.

In the last year, TG Therapeutics(TGTX) shares hit a 52-week high of $59.30 and a 52-week low of $25.28.

In the last year, TG Therapeutics(TGTX) shares hit a 52-week high of $59.30 and a 52-week low of $25.28.

TGTX News

Simply Wall St 5h
TG Therapeutics Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?

TG Therapeutics, Inc. reported past second-quarter 2026 results with revenue of US$240.34 million versus US$141.15 million a year earlier, while net income decl...

TG Therapeutics Is Down 7.4% After Q2 Profit Drop Despite Higher 2026 Revenue Guidance – Has The Bull Case Changed?
Simply Wall St 1d
TG Therapeutics Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings - simplywall.st

...

TG Therapeutics Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings - simplywall.st
Nasdaq 4d
TG Therapeutics Inc. Reports Fall In Q2 Bottom Line

(RTTNews) - TG Therapeutics Inc. (TGTX.OB) reported earnings for second quarter that Dropped, from last year The company's bottom line came in at $7.78 million...

TG Therapeutics Inc. Reports Fall In Q2 Bottom Line

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
0%
Sell
12.5%

People also own

Based on the portfolios of people who own TGTX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.